Trial Profile
Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: a Non-inferiority, Open-label, Randomized-controlled Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Thrombopoietin
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 01 Oct 2022 Primary endpoint has been met (The cumulative numbers of platelet engraftment (platelet recovery to 20 X 109/L for seven consecutive days without transfusion) on day 60 after transplantation) , according to Results published in the Hematological Oncology
- 01 Oct 2022 Results published in the Hematological Oncology
- 26 Jul 2022 Status changed from recruiting to completed.